Literature DB >> 15517526

Quantitative determination of the novel anticancer drug E7070 (indisulam) and its metabolite (1,4-benzenedisulphonamide) in human plasma, urine and faeces by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry.

Jan Hendrik Beumer1, Hilde Rosing, Michel J X Hillebrand, Lianda G A H Nan-Offeringa, Karen Foley, S Murray Yule, Albert J R Heck, Jan H M Schellens, Jos H Beijnen.   

Abstract

E7070 (indisulam) is a novel anticancer drug currently undergoing clinical investigation. We present a sensitive and specific method for the quantitative determination of E7070 and its metabolite M1 (1,4-benzenedisulphonamide) in human plasma, urine and faeces. The analytes and their tetra-deuterated analogues, which were used as internal standards, were isolated from the biological matrix by solid-phase extraction with OASIS cartridges (0.5 mL plasma or 1 mL urine) and by liquid-liquid extraction with ethyl acetate at pH 5 (1 mL faecal homogenate). The analytes were separated on a C8 reversed-phase chromatographic column and analyzed using electrospray ionization and tandem mass spectrometric detection in the negative ion mode. The validated concentration ranges in plasma were 0.1-20 microg/mL for E7070 and 0.01-2 microg/mL for M1. In urine and faecal homogenate, a concentration range from 0.05-10 microg/mL or microg/g, respectively, was validated for both analytes. Validation of the plasma assay was performed according to the most recent FDA guidelines. The assay fulfilled all generally accepted requirements for linearity (r > 0.99, residuals between -8 and 10%), accuracy (-13.5 to 1.4%) and precision (all less than 11%) in the tested matrices. We investigated recovery, stability (working solutions at -20 degrees C and at room temperature, biological matrices at -20 degrees C, room temperature and after 3 freeze/thaw cycles; final extracts at room temperature) and robustness. All these parameters were found acceptable. This method is suited for mass balance studies or therapeutic drug monitoring, as demonstrated by a case example showing plasma concentrations and cumulative excretion of E7070 and M1 in urine and faeces. Furthermore, we show the presence of E7070 metabolites in patient urine. 2004 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15517526     DOI: 10.1002/rcm.1699

Source DB:  PubMed          Journal:  Rapid Commun Mass Spectrom        ISSN: 0951-4198            Impact factor:   2.419


  4 in total

1.  Population pharmacokinetic and pharmacodynamic analysis to support treatment optimization of combination chemotherapy with indisulam and carboplatin.

Authors:  Anthe S Zandvliet; Jan H M Schellens; Christian Dittrich; Jantien Wanders; Jos H Beijnen; Alwin D R Huitema
Journal:  Br J Clin Pharmacol       Date:  2008-05-29       Impact factor: 4.335

2.  Incorporation of concentration data below the limit of quantification in population pharmacokinetic analyses.

Authors:  Ron J Keizer; Robert S Jansen; Hilde Rosing; Bas Thijssen; Jos H Beijnen; Jan H M Schellens; Alwin D R Huitema
Journal:  Pharmacol Res Perspect       Date:  2015-03-25

3.  A dose-escalation study of indisulam in combination with capecitabine (Xeloda) in patients with solid tumours.

Authors:  W S Siegel-Lakhai; A S Zandvliet; A D R Huitema; M M Tibben; G Milano; V Girre; V Diéras; A King; E Richmond; J Wanders; J H Beijnen; J H M Schellens
Journal:  Br J Cancer       Date:  2008-04-15       Impact factor: 7.640

4.  A phase I and pharmacokinetic study of indisulam in combination with carboplatin.

Authors:  C Dittrich; A S Zandvliet; M Gneist; A D R Huitema; A A J King; J Wanders
Journal:  Br J Cancer       Date:  2007-02-06       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.